Pt fibeoscan
| Parameter | Value | Significance |
|---|---|---|
| LSM (Liver Stiffness) - Median E | 6.9 kPa | Fibrosis stage |
| IQR/Med | 9% | Reliability indicator |
| CAP (Controlled Attenuation Parameter) | 269 dB/m | Steatosis grade |
| SD | 11 | |
| SWF | 50 Hz | |
| Valid measurements | 10 |
| Stage | kPa Range |
|---|---|
| F0-F1 (no/mild fibrosis) | < 7.0 kPa |
| F2 (significant fibrosis) | 7.0 - 8.7 kPa |
| F3 (advanced fibrosis) | 8.8 - 10.3 kPa |
| F4 (cirrhosis) | > 10.3 kPa |
| Grade | CAP Range |
|---|---|
| S0 (none) | < 238 dB/m |
| S1 (mild, >11%) | 238 - 259 dB/m |
| S2 (moderate, >33%) | 260 - 290 dB/m |
| S3 (severe, >66%) | > 290 dB/m |
Is this reversible
NAFLD fibrosis regression weight loss lifestyle intervention
NAFLD steatosis reversal weight loss
| Intervention | Expected Benefit |
|---|---|
| 5% weight loss | Steatosis reduction (CAP falls) |
| 7-10% weight loss | Fibrosis regression (kPa falls) |
| Mediterranean diet | Reduces hepatic fat independent of weight |
| 150-200 min/week aerobic exercise | Reduces liver fat even without weight loss |
| Control blood sugar (HbA1c < 7) | Slows fibrosis progression |
| Avoid alcohol completely | Prevents additive liver injury |
| Avoid hepatotoxic drugs | NSAIDs, unnecessary supplements - avoid |